Voxeleron LLC was co-founded in 2010 by Daniel Russakoff and Jonathan Oakley to develop state-of-the-art software in the field of computer vision and machine learning. Our specialty is in the development of ophthalmic image analysis software for optical coherence tomography (OCT) imagery. In this area, our personnel have more experience developing and releasing analysis algorithms than any other institution, commercial or academic. Contact us to learn about our products or how Voxeleron LLC could, in a consultancy role, contribute to your organization.
Jonathan Oakley has a B.Sc. in Computer Science from the University of York, England, a Masters from University College, London, and a Ph.D. in medical image processing from the Swiss Federal Institute of Technology. Since then, he has spent almost two decades working on image processing and machine learning algorithm development for KLA-Tencor, Fujifilm and Carl Zeiss Meditec Inc. His research interests are primarily in medical image processing, with a clear emphasis on ophthalmic applications.
Daniel Russakoff received an A.B. in Geophysics from Harvard University and his Ph.D. in Computer Science from Stanford. His research interests are in computer vision and pattern recognition in general, and biomedical image analysis in particular. He has authored numerous conference and journal papers and holds several patents on topics ranging from stereo vision to medical image registration. He has worked as a Computer Scientist at the National Institute of Standards and Technology and as Chief Scientist at Fujifilm’s San Jose Research Lab. His more recent work has been using probabilistic shape analysis and machine learning for segmentation of deformable structures in 2D and 3D radiological images.
Scientific Advisory Board
We are currently in the process of recruiting a scientific advisory board, so please stay tuned for updates. A large focus of our research and development has been in neurological applications of ophthalmic imaging, which we will continue to do. Our concentration, however, has shifted toward ocular diseases, with a focus on prognostics using deep learning. In light of this, we are assembling a Scientific Advisory Board to offer expertise and help guide this research to address the relevant and pressing problems. Further updates to follow.